PT  - JOURNAL ARTICLE
AU  - Marina Petrovic
AU  - Ivan Cekerevac
AU  - Dejan Petrovic
AU  - Rada Vucic
AU  - Ivan Simic
TI  - Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P516
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P516.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P516.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - AIM : Interleukin-33 (IL-33) has recently been implicated in tumor immunity. The aim of this study was to explore the clinical role of serum IL-33 in patients with non-small-cell lung cancer (NSCLC).METHODS:Sera collected from 126 healthy volunteers (HV), 148 patients with benign lung diseases (BLD) and 103 NSCLC cases were subjected to IL-33 ELISA and relationships between serum IL-33 and clinical characteristics were evaluated.RESULTS:Circulating IL-33 levels were higher in the NSCLC group in comparison with the HV and BLD groups (p<0.001). Using a cut-off level 63 pg/ml (95% specificity in the HV group), IL-33 showed a good diagnostic performance for NSCLC. Multivariate survival analysis indicated that serum IL-33 was an independent prognostic factor in the entire NSCLC group [hazards ratio (HR) = 0.69 for low versus high IL-33 levels, 95% confidence interval (CI) 0.54-0.87; p<0.001] and in 71 selected patients with locally advanced or metastatic disease receiving chemoradiotherapy or chemotherapy (HR 0.80, 95% CI 0.49-0.95; p=0.015).CONCLUSIONS:IL-33 is a promising potential diagnostic and prognostic marker in NSCLC, independent of the therapeutic interventionKey words: non-small cell lung cancer, interleukin-33, diagnostic marker, prognostic marker.